Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120-Reference-Cited by-同舟云学术

Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120

Published:2007-02-01 Issue:2 Volume:44 Page:203-212
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Russell Nina D,Graham Barney S,Keefer Michael C,McElrath M Juliana,Self Steve G,Weinhold Kent J,Montefiori David C,Ferrari Guido,Horton Helen,Tomaras Georgia D,Gurunathan Sanjay,Baglyos Lynn,Frey Sharon E,Mulligan Mark J,Harro Clayton D,Buchbinder Susan P,Baden Lindsey R,Blattner William A,Koblin Beryl A,Corey Lawrence

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference34 articles.

1. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.;Clements-Mann;J Infect Dis,1998

2. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule.;Horig;Cancer Immunol Immunother,2000

3. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.;Wright;J Infect Dis,2004

4. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.;Gupta;J Acquir Immune Defic Syndr,2002

5. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.;Evans;J Infect Dis,1999

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial;Vaccine;2023-04

2. HLA-II-Associated HIV-1 Adaptation Decreases CD4 ⁺ T-Cell Responses in HIV-1 Vaccine Recipients;Journal of Virology;2022-09-14

3. Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature;Scientific Reports;2020-08-03

4. Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition;PLOS Pathogens;2020-03-12

5. Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV;Vaccines;2019-09-19